SAN DIEGO, CA – December 18, 2023 – Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology immunotherapeutics, is excited to announce that it has been selected by Pharma Tech Outlook as a Top 10 Biotech Startup in 2023 for its groundbreaking approach to cancer treatment. Pharma Tech Outlook featured Antharis’ innovative use of monoclonal antibodies (mAbs) to harness and enhance the body’s immune system, offering new hope for patients battling a variety of cancer types, against which there are currently no effective treatments.
Unlike traditional treatments that directly target cancer cells, Antharis Therapeutics focuses on empowering the immune system to recognize and combat cancer. Several of the company’s mAbs modulate immune cells to identify and eliminate diseased cells, providing a unique, dynamic and multi-layered approach to fighting cancer across various stages of disease progression. This distinctive strategy, combined with advanced technologies, has allowed Antharis to build one of the most comprehensive portfolios of therapeutic mAbs in the industry.
“In my view, the future of the pharmaceutical sector will rely heavily on biotherapeutics, particularly monoclonal antibodies, as they tend to exhibit superior effectiveness in treating disease and elevated safety for patients,” said Dr. Raphael Ribeiro-Pinaud, CEO and Chairman of Antharis Therapeutics.
The feature also explores the cutting-edge technologies Antharis employs, such as DNA-based immunizations and innovative cloning and screening methods, which significantly improve the success rate of identifying and developing therapeutically-effective antibodies. Additionally, the company’s recent strategic acquisitions of Cassyni Biopharma and Galileo Biotech have strengthened and streamlining R&D processes and manufacturing operations.
With a strong multidisciplinary team and visionary leadership under Dr. Ribeiro-Pinaud, Antharis Therapeutics is transitioning from a preclinical to a clinical-stage company, and holds the potential to revolutionize the field of cancer research and treatment. The company’s unique approach and continued success underscore its commitment to advancing biotherapeutics as a safer, more effective alternative to traditional therapies.
To read the full feature and learn more about how Antharis Therapeutics is changing the future of cancer treatment, please visit Pharma Tech Outlook here.
About Antharis Therapeutics
Antharis Therapeutics is a leading biopharmaceutical company dedicated to developing cutting-edge therapies that leverage the power of the immune system. Specializing in monoclonal antibodies, Antharis focuses on addressing unmet medical needs across oncology, neurological disorders, and infectious and inflammatory diseases. With a robust portfolio and strategic acquisitions, the company is committed to advancing scientific innovation and improving patient outcomes worldwide.
